North China Pharmaceutical Co Ltd Capital Reinvestment Ratio
North China Pharmaceutical Co Ltd capital reinvestment ratio. North China Pharmaceutical Co Ltd (600812) has a Capital Reinvestment Ratio of 0.85x as of September 2025, meaning it reinvests 1% of its operating cash flow (CN¥170.24 Million) in capital expenditures (CN¥144.38 Million). See North China Pharmaceutical Co Ltd (600812) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of North China Pharmaceutical Co Ltd (2000–2025)
Capital reinvestment ratio of North China Pharmaceutical Co Ltd from 2000 to 2025. This chart tracks North China Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 22 annual periods. See North China Pharmaceutical Co Ltd leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
North China Pharmaceutical Co Ltd Capital Reinvestment Ratio by Year (2000–2025)
North China Pharmaceutical Co Ltd capital reinvestment ratio by year from 2000 to 2025. For the full cash flow conversion analysis, see 600812 operating cash flow.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.46x | CN¥1.18 Billion | CN¥542.01 Million | ▼ -27.8% |
| 2024 | 0.64x | CN¥1.23 Billion | CN¥784.22 Million | ▲ +4.9% |
| 2023 | 0.61x | CN¥1.02 Billion | CN¥623.04 Million | ▲ +11.2% |
| 2022 | 0.55x | CN¥1.00 Billion | CN¥549.58 Million | ▲ +5.0% |
| 2021 | 0.52x | CN¥1.05 Billion | CN¥547.50 Million | ▼ -61.1% |
| 2020 | 1.34x | CN¥752.15 Million | CN¥1.01 Billion | ▲ +51.9% |
| 2019 | 0.88x | CN¥732.97 Million | CN¥645.97 Million | ▲ +34.7% |
| 2018 | 0.65x | CN¥774.33 Million | CN¥506.64 Million | ▼ -53.0% |
| 2017 | 1.39x | CN¥287.25 Million | CN¥399.69 Million | ▼ -53.7% |
| 2015 | 3.00x | CN¥122.50 Million | CN¥367.81 Million | ▲ +5.3% |
| 2014 | 2.85x | CN¥90.56 Million | CN¥258.30 Million | ▼ -42.9% |
| 2011 | 4.99x | CN¥227.60 Million | CN¥1.14 Billion | ▲ +1279.5% |
| 2009 | 0.36x | CN¥1.01 Billion | CN¥366.10 Million | ▲ +184.8% |
| 2008 | 0.13x | CN¥1.09 Billion | CN¥138.00 Million | ▼ -14.1% |
| 2007 | 0.15x | CN¥664.37 Million | CN¥98.27 Million | ▲ +70.8% |
| 2006 | 0.09x | CN¥597.12 Million | CN¥51.72 Million | ▼ -89.5% |
| 2005 | 0.82x | CN¥224.17 Million | CN¥184.67 Million | ▼ -26.6% |
| 2004 | 1.12x | CN¥310.39 Million | CN¥348.50 Million | ▲ +47.2% |
| 2003 | 0.76x | CN¥580.32 Million | CN¥442.77 Million | ▲ +150.8% |
| 2002 | 0.30x | CN¥738.50 Million | CN¥224.68 Million | ▼ -41.7% |
| 2001 | 0.52x | CN¥367.28 Million | CN¥191.79 Million | ▼ -28.5% |
| 2000 | 0.73x | CN¥133.49 Million | CN¥97.52 Million | — |